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Abstract
Paediatric cancer survival rates have increased dramatically in the last 20 years. With 
decreased mortality comes increased long-term morbidity. Cardiovascular disease is the 
leading cause of secondary morbidity and mortality of childhood cancer survivors. The 
most common chemotherapeutic agents in treatment regimens are implicated in chemo-
therapy-induced cardiomyopathy. The clinical presentation is rarely uniform and may 
manifest in symptoms besides chest pain, shortness of breath or decreased exercise toler-
ance. In addition to symptomatic patients, asymptomatic patients are especially impor-
tant to screen as the effects of cardiac toxicity are reversible if caught early. There are new 
techniques more sensitive than traditional 2D echocardiography ejection fraction that 
may lead to earlier detection of cardiac dysfunction. Treatment methods have changed 
little in the recent past with the exception of miniaturization of support devices allowing 
for cardiac recovery or bridge to cardiac transplant.
Keywords: cardiomyopathy, cardio-oncology, heart failure, cardiotoxicity, 
anthracyclines
1. Introduction
Cardiovascular compromise is the leading cause of morbidity and mortality of childhood 
cancer survivors [1]. As paediatric cancer treatment improves and survival increases, there 
is a significant amount of that population with resultant secondary morbidities who need 
to be monitored. Paediatric cancer survivors have been found to have an eight-time greater 
risk of dying from a cardiovascular event compared to their peers [2]. Routine monitoring is 
paramount because progressive cardiac dysfunction in children may not be present in typical 
fashion [3]. Children may also be too young to effectively communicate what they are feel-
ing, requiring the provider to obtain a specific history from the caretaker, a detailed physical 
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exam and often adjunct imaging and laboratory studies. When cardiac dysfunction is found 
early, working with the oncology team to limit further cardiotoxic medications, if possible, as 
well as implementing heart failure management strategies may lead to full cardiac recovery.
2. Clinical presentation and initial assessment
Depending on the chemotherapeutic agent used, heart failure can present in 0.5–28% of 
patients [2], and a larger percentage can have other cardiac-related dysfunctions. The typi-
cal presentation of heart failure is dyspnoea, oedema and chest pain [4]. However, more 
than half of patients who present to an emergency department for cardiomyopathies have a 
primary complaint of gastrointestinal symptoms such as abdominal pain, decreased appe-
tite, nausea or vomiting. Symptoms can be often vague, and a high index of suspicion is 
needed to prompt further evaluation. In babies, the history should include questions such as 
changes in feeding patterns, decreased tolerance of feeds, tiring or sweating with feeds and 
poor weight gain. In older children, the history should include questions about keeping up 
with peers, changes in weight (either increased or decreased), puffiness, nausea or vomiting, 
decreased appetite, overall level of energy and if they’re needing more pillows to sleep on at 
night. Asymptomatic patients may also have small decreases in cardiac function that can be 
clinically important.
The physical exam should include vital signs such as heart rate, blood pressure, pulse oxim-
etry, respiratory rate, weight and height. A thorough cardiac exam includes palpation of the 
chest wall for chest wall abnormalities as well as feeling for a point of maximal impulse. When 
auscultating it is important to assess for murmurs, an abnormally split S2, an S3 or S4, a P2, 
as well as a rub or distant heart sounds. Jugular venous distension should be noted as well 
as any carotid bruits. The extremities should be examined for pulses, oedema, capillary refill 
or nodules. The nail beds should be examined looking for splinter haemorrhages as a sign of 
endocarditis. The abdomen should be palpated for liver and spleen size if able.
These patients have accelerated coronary artery disease [5] that can have a varying presen-
tation from being asymptomatic to acute coronary syndrome and myocardial infarction. 
Hypertension manifests in this patient population secondary to reduced nitric oxide pro-
duction, and screening blood pressures should be obtained during clinic visits [6]. Long-
standing hypertension can lead to left ventricular hypertrophy and ultimately dysfunction. 
Paediatric cancer survivors are also at risk for increased thromboembolic events and may 
present with tachycardia, chest pain, shortness of breath and symptoms, which could be due 
to pulmonary embolism. Patients with unilateral leg pain should be worked up for deep vein 
thromboses.
3. Common cardiotoxic agents
Many conventional forms of chemotherapy are aimed at causing cancer cell injury and 
death; however, they can also induce myocardial cell damage. This injury from agents such 
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as anthracyclines, antimetabolites and cyclophosphamide can lead to acute or chronic left 
ventricular dysfunction [2]. Right ventricular dysfunction is rare, but some drugs such as 
anthracyclines, cyclophosphamide and 5-fluouracil can cause right ventricular systolic and 
diastolic function [7]. It is important to be aware of the offending agents in order to minimize 
exposure, if clinically possible, in a failing heart. Left ventricular dysfunction from anthracy-
cline exposure has been well studied and is dose dependent. Thus, it is important to have a 
clear record of the lifetime dosage a patient receives of chemotherapeutic agents. Table 1 lists 
the most common cardiotoxic agents and their toxic dose ranges.
Every patient is different, which is why routine screening of cardiac dysfunction is recom-
mended even below the toxic level range as well as with drugs not typically associated with 
cardiac dysfunction. Radiation can also be cardiotoxic leading to myocardial oedema, fibrosis 
and necrosis, and total radiation dose as well as the area radiated should be recorded.
4. Screening
4.1. Electrocardiography
A baseline electrocardiogram (ECG) should be obtained on all patients before undergoing 
chemotherapy. ECGs are relatively inexpensive, quick and noninvasive screening tests that 
give information about chamber sizes, depolarization abnormalities, rhythm disturbances 
and conduction abnormalities. Some of the chemotherapeutic agents or supportive medica-
tions prolong QT intervals so it is important to manually calculate a QTc before initiating 
therapy as well as while on QT-prolonging medications. ECGs can be repeated during imag-
ing follow-up or with any concerning symptoms. Twenty-four hour Holter monitors should 
be ordered as clinically indicated.
Drug Toxic dose range Cardiac toxicity Frequency
Doxorubicin >450 mg/m2 LV dysfunction >5% [6]
Epirubicin >900 mg/m2 LV dysfunction >5% [6]
Idarubicin 150–290 mg/m2 LV dysfunction, heart failure 5–18% [8]
Docetaxel Arrhythmia, heart failure 5% [9]
Cyclophosphamide >100–120 mg/kg LV dysfunction 2–10% [9]
Ifosfamide >10 mg/m2 Arrhythmias Unknown
Capecitabine Conventional dose Cardiac ischemia 1–18% [10]
Fluorouracil Conventional dose Arrhythmias, myocardial ischemia 1–18% [10]
Arsenic trioxide Conventional dose QTc prolongation >5% [6]
Cisplatin Diastolic dysfunction, myocardial 
ischemia, hypertension [11]
>6% (major cardiac event)
Table 1. Common cardiotoxic chemotherapeutic agents and their cardiotoxicity.




Echocardiography is the most widely used imaging modality for screening cardiac dysfunction 
and is an important noninvasive manner to follow up cardiac function over time. The advan-
tages of echocardiography are that it is widely available in paediatric cardiology clinics, can 
usually be performed without sedation and is noninvasive, and a targeted function exam can 
be performed relatively quickly in the inpatient and outpatient setting. It is recommended that 
all patients have a complete paediatric echocardiogram before the initiation of chemotherapy. 
All structures of the heart should be visualized including coronary arteries, the pulmonary 
veins and the aortic arch during the first echocardiogram. If all structures are seen adequately 
during the first echocardiogram, subsequent echocardiograms can be targeted function exams. 
The cardiac valves should be visualized on all exams as these patients have an increased risk of 
endocarditis, nonbacterial thrombotic endocarditis as well as radiation-induced heart disease 
affecting valves [7]. Transthoracic echocardiography is acceptable for looking for endocarditis 
if there are clear windows to the heart valves; otherwise depending on the index of suspicion, 
transoesophageal echocardiography is indicated as the gold standard.
Surveillance echocardiograms, or equivalent cardiac imaging, should be performed any-
where from yearly to every 5 years depending on doxorubicin isotoxic equivalent dosing, age 
and radiation for asymptomatic children with stable function [12]. It is recommended that 
any decrease in serial function should be assessed yearly. Also, patients with clinical changes 
should be assessed more frequently.
Historically, left ventricular ejection fraction (EF) has been used to quantitate cardiac function 
over time. While EF is an adequate gross marker of cardiac function, it may not be sensitive 
enough to detect early cardiac dysfunction [13–15]. Zito et al. demonstrated that there is enough 
variability in EF measurements that it is not sensitive to detect a decrease in EF less than 10% 
[7]. If one is using EF as their main determinant of cardiac function, they may miss patients 
who have a significant decrease in cardiac function that may alter the course of therapy.
Some centres rely on indices of cardiac function other than EF. Strain and strain rate have been 
found to detect cardiac dysfunction earlier than a decrease in LV systolic function [16]. Strain is 
a measure of myocardial deformation or the fractional change in the length of a myocardial seg-
ment. Strain can be measured by tissue Doppler imaging (TDI) as well as speckle-tracking echo-
cardiography (STE). Each of these methods requires adequate 2D echocardiographic imaging 
windows in order to process the image. TDI is angle dependent, requiring the plane of the ultra-
sound to be in line with the tissue being interrogated. One benefit of STE is that it is not angle 
dependent. Speckle tracking can determine peak systolic global longitudinal strain (GLS), which 
is becoming a commonly accepted method for evaluating myocardial function [17]. Figures 1 
and 2 demonstrate examples of normal vs abnormal global and regional strain, respectively. This 
method is quite useful for early detection of cardiotoxicity. It is likely that all of these indices used 
in conjunction with one another will provide the best insight to the cardiac status of the patient.
Diastolic function must also be evaluated during an echocardiographic evaluation of a pae-
diatric cancer patient. Diastolic dysfunction may proceed to systolic deterioration and can 
indicate a need for closer follow-up as it has been reported that it can be a predictor of sub-
sequent deterioration [18]. Diastolic dysfunction can be detected with a decrease in early to 
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late ventricular filling velocities (E/A ratio), an increased E/e′ ratio, enlargement of the atria 
and an increase in isovolumic relaxation time. TDI-derived peak early and late diastolic myo-
cardial velocities of the right ventricular free wall, left ventricular lateral wall and septum are 
decreased in patients with myocardial dysfunction when compared with controls [19].
Figure 1. (A) Longitudinal strain analysis of the left ventricle, with both regional and global longitudinal strain reported. 
The six segment strain curves from the apical 4-chamber, apical 2-chamber and apical long axis are shown, as well as 
a “bullseye” view overlaying the longitudinal strain for each segment. (B) Segmental strain for the apical 4-chamber 
view, including contours of the left ventricle. Global longitudinal strain of the entire 4-chamber slice is normal at −22.8%.
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Figure 2. (A) Abnormally diminished regional and global longitudinal strain in a patient who has anthracycline-induced 
cardiomyopathy. Note the decreased regional strain values in nearly every segment, including positive strain (stretch of 
the muscle) during systole, indicating dyssynchrony. (B) Abnormally diminished global longitudinal strain of the entire 
4-chamber slice at −4.8%. Note the strain waveforms above baseline which represent segments stretching during systole 
instead of contracting (indicative of dyssynchrony).
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Three-dimensional echocardiography is being increasingly used as a more accurate measurement 
of left ventricular systolic function. Where, as previously described, 2D EF may be an inadequate 
measurement of systolic function, 3D echocardiography is a more sensitive method to detect 
decreased LV contractility than fractional shortening by M-mode or EF by 2D [20]. Figure 3 shows 
an example of how 3D echocardiography is used clinically in patients receiving anthracyclines. 
If the patient has poor acoustic windows, however, 3D measurements will be unsatisfactory as 
these measurements rely on clear 2D acquisition. Besides EF, 3D speckle-tracking echocardiogra-
phy is an emerging technique [4]. A 3D evaluation avoids the geometric assumptions of 2D imag-
ing and shows good correlation of decreased myocardial contractility compared to MRI findings. 
At this time, 3D STE is largely experimental and not widely available in most echo laboratories.
4.3. Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging (CMRI) is increasingly playing a larger role in the imag-
ing of paediatric cancer survivors. It allows for tissue characterization, identification of areas 
of fibrosis or oedema as well as a more precise and reproducible measurement of cardiac 
function than echocardiography. There is no need in CMRI for the geometrical assumptions 
to inherent in 2D echo, which can lead to imprecise echocardiographic measurements, and 
there is no need for optimal acoustic windows [21]. In paediatric cancer patients, minimal 
decreases in systolic function may lead to a change in management; thus, a sensitive method 
such as CMRI is useful for monitoring.
Figure 3. A three-dimensional reconstruction of the left ventricle in a patient receiving anthracyclines. Care is taken to 
show accurate contouring of the endocardial border in multiple imaging planes. Output includes end-diastolic volume, 
end-systolic volume and ejection fraction.
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Chemotherapy, as expected, can produce myocardial changes such as tissue fibrosis, oedema 
and even necrosis. Other imaging modalities are not as sensitive as CMRI in detecting these 
changes, and CMRI may help in determining a nidus for an arrhythmia or differentiating poten-
tially reversible vs. irreversible causes of myocardial depression. T2-weighted sequences are 
useful for determining oedema as these areas reveal a hyperintense signal. There is evidence 
that myocardial oedema is related to subsequent decreased RV function. T2 mapping can also 
be used to follow the course of a patient over time. The clinical benefit of this is being investi-
gated and with time it is likely that there will be a more useful correlation with clinical outcomes 
[21]. Late gadolinium enhancement is useful in detecting areas of fibrosis or ischemia and can 
help determine prognosis in cardiomyopathies [22]. Figure 4 shows an example of how CMRI 
can be used to detect scar and fibrosis by late gadolinium enhancement. This technique uses a 
T1 inversion sequence about 10 minutes after injection of a gadolinium-based contrast. CMRI 
can also quantify myocardial perfusion, helpful for the diagnosis of coronary artery disease [23].
While 3D echocardiography is emerging, CMRI has a higher sensitivity of detecting a left 
ventricular ejection fraction <50% [24]. CMRI is also useful in characterization of the right 
Figure 4. Cardiac MRI demonstrating scar and fibrosis using a late gadolinium enhancement technique.
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ventricle because of its irregular shape that is not amenable to geometrical formulas. Although 
right ventricular dysfunction is not as common as left ventricular dysfunction in paediatric 
heart transplant survivors, its consequences can be just as severe.
CMRI can have its downside, especially in children, as it requires the patient to lie still, which 
may be difficult for young children. Anaesthesia is often necessary for an optimal exam of a 
child. Also, because most CMRI images require ECG gating CMRI and be difficult or impos-
sible in the setting of arrhythmias. Metallic implants are often contraindicated with CMRI, or 
if placed in the thorax, they may produce significant artefact, which obscures images.
5. Biomarkers
Biomarkers can be used in conjunction with history, physical examination and imaging 
modalities to gather information on a patient’s clinical status. Unfortunately, there is no single 
biomarker that can predict the cardiac prognosis of a patient.
Cardiac troponins are a widely used biomarker in the field of cardiology and have been found 
to be useful in evaluating anthracycline-induced cardiomyopathies [25]. Troponin I and tro-
ponin T are both sensitive and specific to cardiac damage. The troponin complex is on the thin 
filament of the contraction mechanism and is important in excitation-contraction coupling 
in the heart [26]. Cardiac troponin I increases with anthracycline exposure and appears to 
be dose related. Increased cardiac troponin T levels in the first 90 days of therapy have been 
shown to correlate with cardiotoxicity at 4 years of follow-up [25].
B-Natriuretic peptide (BNP) and NT-pro-B-natriuretic peptide (proBNP) are closely related 
cardiac biomarkers that can aid clinical management of heart failure. Impaired ventricular 
function leads to greater wall stress, which triggers the synthesis of pre-pro-B-type natri-
uretic; this is then broken down to proBNP and then cleaved to BNP. The purpose of these 
peptides is to protect the body from volume overload. BNP and proBNP are related but can-
not be used interchangeably as their reference values are different. Also, the half-life of BNP is 
about 20 min where proBNP is about 1–2 h. The result of the release of BNP is smooth muscle 
and myocardial relaxation and diuresis and natriuresis [27]. BNP is elevated in children with 
anthracycline-induced clinical or subclinical heart failure and can be used along with imaging 
to trend the degree of heart failure [28].
Highly sensitive C-reactive protein (hsCRP) has been shown to predict cardiac events in 
adults; however, this was not found to be true in the paediatric population with heart failure, 
so it is not recommended for routine monitoring [29].
6. Management of cardiomyopathy
The best way to manage heart failure secondary to chemotherapy is to have a robust monitor-
ing programme to prevent its occurrence in the first place. Aggressive medical management 
should begin in the asymptomatic patient once early signs of ventricular dysfunction are 
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detected [30]. Cardiotoxic medications should be avoided or minimized if possible to attempt 
to halt further progression.
There are few large multicentre studies in the paediatric literature to guide heart failure 
management so we extrapolate data from adults and apply many of the same principles to 
paediatric heart failure. The common classes of drugs to treat chemotherapy-induced cardio-
myopathy include beta-blockers and angiotensin-converting enzyme inhibitors (ACEis).
6.1. Beta-blockers
Beta-blockers are the most effective when used shortly after anthracycline-induced cardiac 
injury [6]. Beta-blockers have been found to improve cardiac recovery when used as mono-
therapy or in combination with ACEi. Beta-blockers blunt heart rate responses so immuno-
compromised patients on beta-blockers should be monitored closely as their compensatory 
heart rate response may be blunted in times of stress. Adult trials of metoprolol and bisopro-
lol found that those drugs improve symptoms and survival in mild-to-moderate heart failure 
[31, 32]. Beta-blockers can be titrated based on heart rate response, and effective doses vary 
depending on the patient. The mechanism of beta-blockers in heart failure management is not 
completely clear but is thought to have reversed remodelling effects secondary to myocyte 
damage from prolonged adrenergic activation.
6.2. Angiotensin-converting enzyme inhibitors
ACEis are also commonly used in the management of heart failure secondary to chemothera-
peutic cardiotoxicity. ACEis have the ability to decrease cardiac work by decreasing preload, 
afterload and wall stress [33]. They are also felt to improve cardiac remodelling. They should 
be used with caution in patients with renal insufficiency or concurrent treatment with neph-
rotoxic medications. Renal function should be monitored regularly, especially when titrating 
dose. There are several adult studies that showed benefit with ACEi in regard to mortality. 
One in particular suggests that a combination of enalapril and carvedilol (a beta-blocker) may 
increase left ventricular EF when started at the earliest signs of cardiac dysfunction [34]. In 
children, however, enalapril did not reveal an improvement in cardiac function [35].
6.3. Statins
Statins are not as widely used in the paediatric population but have antioxidative and 
anti-inflammatory effects and may play a role in prevention of cardiotoxicity. In adults, a 
retrospective case-control study revealed that patients who received statins at the time of 
anthracycline treatment had a lower incidence of HF at 2.5 years follow-up [36]. Statins are 
safe in children with the proper monitoring; however, their effects on chemotherapy-induced 
cardiomyopathy are unknown.
6.4. Ventricular assist devices
Ventricular assist devices (VADs) can now be considered in children with inotropic-depen-
dent heart failure. The miniaturization of VAD is allowing for more children to be potential 
candidates with newer devices supporting lower body surface areas and weights. Most often, 
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chemotherapy-induced cardiomyopathies are slow to recover function if at all so VAD can be 
used as a bridge to transplant or in some cases, recovery [23]. VAD can allow patients to be dis-
charged from the hospital, while they are awaiting a heart transplant or recovery. These devices 
are not without risks, however. Complications such as bleeding, thromboemboli or infection 
are not uncommon and require close monitoring. The proximity to the hospital as well as the 
social support system should also be considered when deciding to implant a VAD in a patient.
6.5. Heart transplantation
The definitive treatment for heart failure not responsive to medical therapy is transplantation. 
Some centres consider transplantation if a patient has been cancer-free for 5 years and are not 
requiring ongoing cardiotoxic medications. There may be exceptions based on the clinical pic-
ture. Unfortunately, immunosuppressive medications required for heart transplants decrease 
the body’s ability to detect and destroy cancer cells so it is not uncommon for secondary 
malignancies to occur. While transplantation can be life-saving, the cardiac graft has a limited 
lifespan so the decision to proceed with transplantation should be carefully weighed.
7. Conclusion
Cardiac dysfunctions secondary to cancer treatments are not uncommon. Unfortunately, 
there have been few breakthrough treatment modalities to treat childhood cancer survivors 
with heart failure; thus, it is important that these patients are having routine cardiac sur-
veillance to detect cardiac dysfunction before it is severe or the patient is symptomatic. This 
would allow for altering the treatment plan as well as starting on supportive therapy earlier, 
which may be beneficial allowing for full cardiac recovery. Institutions should develop robust 
protocols and have close collaboration with oncologists and cardiologists to ensure that these 
patients are receiving optimal care.
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